U.S. CDMRP – Peer Reviewed Cancer Research Program | Research Funding
Event details
| Date | 26.06.2026 |
| Category | Call for proposal |
| Event Language | English |
Aim: Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the 2026 Peer Reviewed Cancer Research Program (PRCRP). Several award programs are available:
Funding:
Idea Award: max. $600K
Impact Award: $1.5M-$2M
Clinical Trial Award: max. $4.5M
Note: Cost caps are total costs (direct plus indirect costs). In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding
Duration:
Idea Award: 2 years
Impact Award: 3 years
Clinical Trial Award: 4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 26 June 2026, 5:00 p.m. Eastern time
Full Application Deadline: 05 October 2026, 11:59 p.m Eastern Time
Further information:
Bladder cancer • Blood cancers • Brain cancer • Colorectal cancer • Endometrial cancer • Esophageal cancer • Germ cell cancers • Glioblastoma • Liver cancer • Lymphoma • Mesothelioma • Metastatic cancers • Myeloma • Neuroblastoma • Neuroendocrine Tumors • Pediatric, adolescent, and young adult cancers1 • Pediatric brain tumors • Sarcoma • Stomach cancer • Thyroid cancer
- The Idea Award supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or basic cancer research. The advancement of knowledge in cancer research, patient care, and/or treatment options in the Military Health System (MHS) is critical to active-duty Service Members, Veterans, other military beneficiaries, and the American public.
- The Impact Award supports mature research that will have a near-term impact on clinical cancer care in one of the Topic Areas. Applicants must consider how the research project will lead to the advancement of knowledge in cancer research, patient care and/or treatment options in the MHS.
- The Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations.
Funding:
Idea Award: max. $600K
Impact Award: $1.5M-$2M
Clinical Trial Award: max. $4.5M
Note: Cost caps are total costs (direct plus indirect costs). In accordance with EPFL guidelines, budgets should include a 20% overhead, and the total budget must remain within the grant’s maximum allowable funding
Duration:
Idea Award: 2 years
Impact Award: 3 years
Clinical Trial Award: 4 years
Eligibility: Applicants from international organizations or institutions are eligible to apply, and there are no citizenship restrictions. Independent investigators at all career levels are eligible.
How to Apply: Pre-applications are submitted through the eBRAP platform. They should contain contact information, a letter of intent, and a list of collaborators and key personnel as suggested on the platform. Full applications will be made via a Grants.gov workspace.
Pre-Application Deadline: 26 June 2026, 5:00 p.m. Eastern time
Full Application Deadline: 05 October 2026, 11:59 p.m Eastern Time
Further information:
- To find the full program announcements and to start your pre-application see here
- A useful summary of each call can be found here
- For questions about the eBRAP or Grants.gov platforms, contact the Research Office.
- Grants.gov Funding Opportunity Numbers:
- Idea Award: HT942526PRCRPIA
- Impact Award: HT942526PRCRPIPA
- Clinical Trial Award: HT942526PRCRPCTA
Bladder cancer • Blood cancers • Brain cancer • Colorectal cancer • Endometrial cancer • Esophageal cancer • Germ cell cancers • Glioblastoma • Liver cancer • Lymphoma • Mesothelioma • Metastatic cancers • Myeloma • Neuroblastoma • Neuroendocrine Tumors • Pediatric, adolescent, and young adult cancers1 • Pediatric brain tumors • Sarcoma • Stomach cancer • Thyroid cancer
Practical information
- General public
- Free